Abstract C020: First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumors
Alison M. Schram(Memorial Sloan Kettering Cancer Center), Howard A. Burris(Deaconess Hospital), Justin Meyerowitz(Stanford University), Sumit Kar(Revolution Medicines (United States)), Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Zhican Wang(Revolution Medicines (United States)), Eric B. Haura(Moffitt Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), W. Clay Gustafson(Revolution Medicines (United States)), Pamela N. Münster(University of California, San Francisco), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Abdul Rafeh Naqash(Oklahoma City University), Tao Lin(Chengdu University), Anna Capasso, Michael L. Cheng(University of California, San Francisco), Bojena Bitman(Revolution Medicines (United States))
Cited by 8
Related Papers
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k